The PrEP Costing Guidelines provide a framework for estimating the cost of providing pre-exposure prophylaxis (PrEP), which is the use of antiretroviral (ARV) drugs for preventing the acquisition of HIV infection.
Update on recommendations on antiretroviral regimens for treating and preventing HIV infection: In 2016, WHO published the consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and recommended tenofovir disoproxil fumarate (TDF
The Partnership for HIV-Free Survival (PHFS) was designed to use basic quality improvement practices to reduce mother-to-child transmission of HIV and increase child survival through improvements in (1) antiretroviral therapy uptake and retention among HIV-positive pregnant women and mothers, (2)
Young women who have sexual relationships with older men often are dealing with inequitable power dynamics, little capacity to negotiate safe sex or to refuse sex, and—therefore —a greater risk of acquiring HIV.
As part of its Monitoring, Evaluation, and Reporting (MER) guidance, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) released Version 2.3 in September 2018, which includes revised indicators for orphans and vulnerable children (OVC) programs.
With funding from PEPFAR, the Human Resources for Health in 2030 (HRH2030) has developed, piloted, and field-tested a tool to help health facility staff and district health management teams optimize their health workforce for the roll-out of “Test and Start” utilizing